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A B S T R A C T
Background: Clinician-assessed Expanded Disease Status Scale (EDSS) is gold standard in clinical investigations
but normally unavailable in population-based, patient-centred MS-studies. Our objective was to develop a self-
reported gait measure reflecting EDSS-categories.
Methods: We developed the self-reported disability status scale (SRDSS) with three categories (≤3.5, 4–6.5,≥7)
based on three mobility-related questions. The SRDSS was determined for 173 persons with MS and validated
against clinical EDSS to calculate sensitivity and specificity.
Results: Accuracy was 88.4% (153 correctly classified) and weighted kappa 0.73 (0.62–0.84). Sensitivity/spe-
cificity-pairs were 94.5%/77.8%, 69.0%/94.7% and 100%/98.2% for SRDSS ≤3.5, 4–6.5 and ≥7, respectively.
Conclusions: Self-reported SRDSS approximates EDSS-categories well and fosters comparability between clinical
and population-based studies.
1. Introduction
The expanded disability status scale (EDSS) is the most commonly
used outcome measure in clinical research in the field of MS. Despite
acknowledged shortcomings (gait-focused, inaccurate picture of cog-
nition, substantial interrater-variability, impairment-centred), the EDSS
is still considered the gold standard for measuring disability (Bovis
et al., 2018; Meyer-Moock et al., 2014; Twork et al., 2010). By contrast,
the EDSS bears little meaning to persons with MS (PwMS). In a
questionnaire of the Swiss MS Registry (SMSR), only 11% knew their
EDSS-score (unpublished data). This lack of knowledge amongst PwMS
about the own EDSS poses substantial challenges for observational
studies relying on patient self-reports such as the SMSR or the UK MS
Registry, because this hinders interstudy comparability (Ford et al.,
2012; Puhan et al., 2018; Steinemann et al., 2018).
Although self-reported EDSS-proxy measures have been proposed,
no instrument has emerged as a standard (Collins et al., 2016).
Therefore, there is still a need for short, reliable, and robust instruments
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for self-assessments of disability status that offer comparability with the
ubiquitous EDSS. Our aim was 1) to develop a patient-based proxy-
measure of easy-to-assess information which reflects predefined, clin-
ical EDSS-categories and 2) to validate the measure with clinical EDSS-
values.
2. Methods
The self-reported information was available from the SMSR, which
is a prospective, patient-centred, ongoing study of adult PwMS in
Switzerland (n = 2159, as of 25 November 2019) (Puhan et al., 2018;
Steinemann et al., 2018). The clinical EDSS-values were available from
two sources: on the one hand, key information such as diagnostic dates,
disease severity, symptoms and EDSS were abstracted from medical
records on site in clinics and practices for a 10% subpopulation of the
SMSR (Steinemann et al., 2018). On the other hand, double participa-
tion in the SMSR and the clinic-based Swiss MS cohort study (SMSC),
which includes EDSS-scores, allowed the linkage of records (Disanto
et al., 2016). Where both data sources were available, the SMSC data
were included (SMSR: 71%, SMSC: 29%). The study was approved by
the ethics committee of the canton of Zurich (PB-2016–00894, BASEC
2019–01027) and written informed consent was obtained from all
participants (Steinemann et al., 2018).
The self-reported disability status scale (SRDSS) defined in this
study was constructed to represent mobility-centred descriptions of
predefined EDSS-categories (Wallin et al., 2019). It was based on three
self-reported questions with no missing values allowed. The first
question concerned the distance PwMS could walk in flat terrain
(<10 m, 10 to 500 m, ≥500 m), the second whether PwMS used any
walking aids (cane or rollator), and the third if PwMS used a wheel-
chair. Following the pre-defined decision tree, the branches resulted in
three outcomes (SRDSS ≤3.5, 4–6.5, ≥7) (supplementary material
Table A1). Branches resulting in the same outcome were collapsed
(Fig. 1).
The comparison was based on 173 PwMS, for which clinical EDSS-
assessments were available within± 365 days of the SMSR survey data
(median difference: 65 days, inter-quartile range (IQR): 19–122). The
agreement between the reported EDSS-category (≤3.5, 4–6.5, ≥7) and
the constructed SRDSS (≤3.5, 4–6.5, ≥7) was analysed by calculating
the overall accuracy, the linear weights weighted kappa and the group-
specific sensitivity and specificity. As a sensitivity analysis, the two
EDSS-value sources were analysed separately. All statistical analyses
were performed using STATA, version 13.
3. Results
The study population consisted of 173 PwMS with a median age of
48 (IQR: 38–55) and 74% women. The predominant disease course was
relapsing-remitting MS (73%), followed by secondary-progressive MS
(15%), primary-progressive MS (7%) and clinically-isolated syndrome
(4%). The median disease duration was 7 years (IQR: 3–15).
Of the 173 PwMS, the EDSS- and SRDSS-categories matched for 153,
resulting in an accuracy of 88.4% and a weighted kappa of 0.73
(0.62–0.84). The sensitivity/specificity pairs were 94.5%/77.8%,
69.0%/94.7% and 100%/98.2% for SRDSS ≤3.5, 4–6.5 and ≥7, re-
spectively (Table 1). The results of the sensitivity analysis, limiting the
source of the clinical EDSS to either the medical record abstraction
Fig. 1. Simplified decision tree to construct the self-reported disability status scale (SRDSS).
Table 1
Contingency table of the SRDSS and the corresponding EDSS-values.
SRDSS EDSS Sensitivity Specificity
≤3.5 4–6.5 ≥7
≤3.5 121 10 0 94.5% 77.8%
4–6.5 7 29 0 69.0% 94.7%
≥7 0 3 3 100% 98.2%
Accuracy 88.4% Kappa 0.73
The sensitivity and specificity refer to SRDSS-specific subgroups (≤3.5, 4–6.5,
≥7). EDSS represents “Expanded Disability Status Scale” and SRDSS “Self-
Reported Disability Status Scale”. Kappa stands for linear weights weighed
Kappa.
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(71%) or the SMSC (29%), were similar (data not shown).
4. Discussion
We developed the SRDSS, a proxy-measure to estimate EDSS-cate-
gories based on easy-to-assess self-reported data. The accuracy of the
SRDSS was good (88.4%, weighted kappa 0.73) and only the middle
SRDSS-category showed misclassification problems (sensitivity of
69.0%).
The SRDSS is a convenient tool to estimate EDSS-categories based
on three simple questions. These questions can be assessed quickly, and
self-reported answers can be given orally, online or on paper. This
brevity and flexibility can potentially reduce the under-representation
of elderly and severely disabled persons. Furthermore, concerns re-
garding the self-report of walking distances play only a minor role due
to the reduced granularity of the answer options (Skjerbæk et al.,
2019).
It is important to note that the purpose of the proxy-measure is not
mistaken. The SRDSS is primarily designed to offer an estimate of EDSS-
scores in settings where EDSS-scores are not routinely captured or
cannot be obtained, e.g. in large, patient-centred registries or regions
with poor access to neurologists. In such settings, the SRDSS could help
to contextualise results from observational studies, embedding findings
in a rough estimate of the neurological status. The SRDSS neither re-
places the EDSS nor is it meant as a monitoring tool. For these purposes,
it lacks sensitivity and the level of detail needed.
Further limitations of the SRDSS are related to its respective pur-
pose. An outcome measure, which is heavily weighted towards a pa-
thological extent of the neuroaxis, is unlikely to suffice ecologically
relevant MS-studies. Hence, in the context of the latter, it might be
more important to document changes that occur frequently instead of
infrequently, as the additional noise may compromise power. For these
purposes, a self-reported tool might serve as a complementary ap-
proach. However, the complexity and duration of some existing tools
limit their scope and our newly developed SRDSS might help to close
the gap (Leddy et al., 2013). Nonetheless, the SRDSS, also due to its
focus on mobility, lacks sensitivity for the fine-grained differences at
the transitions of categories and therefore is prone to certain mis-
classifications. However, this can also be partially attributed to a tem-
poral difference between SRDSS- and EDSS-measurements, potentially
allowing for relapses and disease progression. Lastly, the SRDSS was
compared in 173 PwMS and a wider validation of the tool is en-
couraged.
In summary, our study shows that the SRDSS can estimate EDSS-
categories based on easy-to-assess self-reported information. It can be
easily implemented and has thus the potential to be used in various
settings, fosters interstudy comparability and increases the value of
PwMS-reported information.
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